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The use of emergency percutaneous transluminal coronary
angioplasty as primary therapy in patients with early acute
myocardial infarction, as detailed in this issue of the Journal
by Rothbaum et al. (I), is an important report of an ag-
gressive procedure expertly and expeditiously applied. It is
a tour de force of this invasive methodology with impressive
clinical results. These results are difficult to compare with
those of other modes of therapy; nevertheless, it is our duty
as clinicians to try to put them into some meaningful context.
Such aggressive management has compelling logic and there
are substantial supporting experimental data documenting
benefit from early reperfusion. It is unfortunate but true,
however, that many newer methods of therapy are often
compared with essentially no treatment rather than with
successive levels of progressively more active pharmaco-
logic therapy.
No prospectively randomized or retrospectively matched
control group was designed into this trial. Furthermore, it
is not clear from the report how many patients, if any, who
presented early to St. Vincent's Hospital with acute myo-
cardial infarction in this 37 month period did not receive
emergency angioplasty. No one was excluded for age, car-
diogenic shock or even ongoing cardiac arrest, but any other
exclusions that would help to define a suitable comparison
group are not specified, if they occurred.
Comparison with GISSI trial. The results in these 151
patients can be compared with the overall mortality as re-
ported by the large Italian study (GISSI) (2) of intravenous
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streptokinase versus "standard" coronary care unit therapy.
That study includes the largest number of patients with early
myocardial infarction studied so far (II ,806 patients ran-
domized) and shows a definite advantage for streptokinase
over ill defined but "standard" therapy. The GISSl mor-
tality rate in patients treated within the first 3 hours of acute
myocardial infarction was 9.2%, and this compares favor-
ably with the overall mortality rate of 8.6% presented by
Rothbaum et al. Some of the patients studied by Rothbaum
et al. were treated after that 3 hour period, but the majority
of these had patent vessels at the time of treatment and
perhaps would have followed a favorable course without
intervention. Randomization in the Italian study began after
admission to the coronary care unit. This delay as well as
protocol restrictions for use of streptokinase may well have
eliminated the patients with early acute arrest who represent
4 of the 13 deaths in the series of Rothbaum et al. When
these patients are excluded, the mortality rate for emergency
angioplasty falls to 6.1% in this small series. If, however,
there were any reason to believe that transportation to the
catheterization laboratory and preparation for angiography
had a role in precipitating the cardiac arrest in any of these
patients, then of course their death would have to be con-
sidered angioplasty related.
Comparison with MIAMI trial. Another group receiv-
ing less aggressive therapy can be found in the MIAMI trial
(3). In that study 2,877 patients received intravenous me-
toprolol a mean of 6.8 hours into an acute myocardial
infarction. The 15 day mortality rate in the treated group
was 4.3%. There were numerous exclusions in that trial,
however. including all patients who had congestive heart
failure, cardiogenic shock or cardiac arrest or who had pre-
viously received either a beta-adrenergic or a calcium chan-
nel blocking agent. Those exclusions probably define a lower
risk subgroup than that of the patients studied by Rothbaum
et al.
Comparison with emergency coronary bypass trial.
Another approach, which might be considered even more
aggressive than that of emergency angioplasty, is the use
of emergency coronary artery bypass surgery as reported by
the Spokane group (4). Their overall mortality rate for 440
patients operated on emergently for acute myocardial in-
farction was 5.2%. Among the 291 patients who were op-
erated on within the first 6 hours of infarction, however,
the mortality rate was 3.8%. The surgeons at Spokane did
exclude patients <40 or >65 years and patients who were
judged by their managing physician to be "too ill" to undergo
emergency surgery. Nevertheless, in that select population,
an unusually talented and dedicated group of physicians
have achieved a mortality for the management of acute
myocardial infarction that is extremely admirable, although
clearly difficult to replicate at other institutions.
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Unstable angina. In all of these series, early aggressive
therapy may well have included management of some pa-
tients who actually had severe unstable angina (formerly
classified as the intermediate coronary syndrome) and whose
condition might never have evolved into acute myocardial
infarction. Such patients cannot be distinguished by current
techniques from patients in the early phase of infarction.
Obviously the most successful therapy will result in no
infarction, and waiting to see whether true infarction will
develop would result in loss of the most valuable time period
for intervention. Such uncertainty reinforces the need for a
contemporaneous control group in evaluating alternative
therapies.
Economic implications. The study of Rothbaum et al.
needs to be taken very seriously in another context, that of
the overall economics of such aggressive treatment. The
American people deserve the best of care delivered in the
most efficient manner and at the least possible cost. If we
conclude that aggressive management, either with primary
emergency angioplasty or emergency bypass surgery, is clearly
the best method of treating patients with early myocardial
infarction, then we need to establish a referral system for
rapid transfer or even in-transport ambulance rerouting to a
centralized treating facility to manage these patients. The
current network for handling major trauma cases is an ob-
vious model. To have cardiac catheterization laboratories
with expert angiographers and cardiovascular surgery backup
in every local hospital constantly ready just to treat the
occasional patient with acute myocardial infarction who ap-
pears very early in his or her course would be extremely
costly, inefficient and probably dangerous. These facilities
will have to be concentrated where expertise is constantly
available. Because of increased volume, the skills of the
angiographers would likely be optimized and the unit cost
per procedure should be minimized.
Clinical implications. Rothbaum et al. clearly show that
emergency primary percutaneous coronary angioplasty is
efficacious for the management of patients with acute myo-
cardial infarction who present early to a tertiary care center
possessing a high level of angioplasty expertise. Before we
establish emergency primary angioplasty as the reference
standard and gear up to provide it nationwide, we need to
know from a large scale randomized controlled trial that
emergency angioplasty alone is clearly superior to either
angioplasty or coronary bypass surgery performed as a staged
procedure after initial reperfusion by thrombolytic therapy
in a local hospital.
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